Jean Jacques Noubiap1, Jobert Richie Nansseu2, Ulrich Flore Nyaga3, Jan René Nkeck3, Francky Teddy Endomba3, Arnaud D Kaze4, Valirie N Agbor5, Jean Joel Bigna6. 1. Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa. 2. Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon. 3. Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon. 4. Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, MD, USA. 5. Ibal Sub-divisional Hospital, Oku, Northwest Region, Cameroon; Department of Clinical Research, Health Education and Research Organization (HERO), Cameroon. 6. Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé, Cameroon; Faculty of Medicine, University of Paris Sud XI, Le Kremlin-Bicêtre, France. Electronic address: bignarimjj@yahoo.fr.
Abstract
BACKGROUND: Although diabetes and poor glycaemic control significantly increase the risk of tuberculosis and adversely affect tuberculosis treatment outcomes, the global burden of diabetes in the context of tuberculosis remains unknown. We did a systematic review and meta-analysis to estimate the prevalence of diabetes among patients with tuberculosis at global, regional, and country levels. METHODS: We searched PubMed, Excerpta Medica Database, Web of Science, and Global Index Medicus to identify studies published between Jan 1, 1986, and June 15, 2017, on the prevalence of diabetes in patients with active tuberculosis, with no language restrictions. Criteria to diagnose tuberculosis and diabetes concurred with WHO guidelines. Methodological quality of eligible studies was assessed, and random-effect models meta-analysis served to obtain the pooled prevalence estimate of diabetes among patients with active tuberculosis, globally. Heterogeneity (I2) was assessed via the χ2 test on Cochran's Q statistic. This study is registered with PROSPERO, number CRD42016049901. FINDINGS: We screened 7565 records of which 200 studies (2 291 571 people with active tuberculosis) were included in meta-analyses. The pooled prevalence of diabetes was 15·3% (95% prediction interval 2·5-36·1; I2 99·8%), varying from 0·1% in Latvia to 45·2% in Marshall Islands. Subgroup and metaregression analyses for identifying sources of heterogeneity showed that four International Diabetes Federation (IDF) regions (North America and Caribbean [19·7%], western Pacific [19·4%], southeast Asia [19·0%], Middle East and North Africa [17·5%]) had significantly higher prevalence estimates than the three others (Africa [8·0%], South and Central America [7·7%], and Europe [7·5%]; p<0·0001). Additionally, the prevalence increased with age, in men, and in countries with low tuberculosis burden. The prevalence of diabetes was decreased in countries that had low incomes and low Human Development Index scores. The form of tuberculosis infection and presence of HIV seemed not to affect the prevalence of diabetes among patients with active tuberculosis. INTERPRETATION: This study suggests a high burden of diabetes among patients with active tuberculosis, with disparities according to age, sex, regions, level of country income, and development. Cost-effective strategies to curb the burden of diabetes among patients with active tuberculosis are needed. FUNDING: None.
BACKGROUND: Although diabetes and poor glycaemic control significantly increase the risk of tuberculosis and adversely affect tuberculosis treatment outcomes, the global burden of diabetes in the context of tuberculosis remains unknown. We did a systematic review and meta-analysis to estimate the prevalence of diabetes among patients with tuberculosis at global, regional, and country levels. METHODS: We searched PubMed, Excerpta Medica Database, Web of Science, and Global Index Medicus to identify studies published between Jan 1, 1986, and June 15, 2017, on the prevalence of diabetes in patients with active tuberculosis, with no language restrictions. Criteria to diagnose tuberculosis and diabetes concurred with WHO guidelines. Methodological quality of eligible studies was assessed, and random-effect models meta-analysis served to obtain the pooled prevalence estimate of diabetes among patients with active tuberculosis, globally. Heterogeneity (I2) was assessed via the χ2 test on Cochran's Q statistic. This study is registered with PROSPERO, number CRD42016049901. FINDINGS: We screened 7565 records of which 200 studies (2 291 571 people with active tuberculosis) were included in meta-analyses. The pooled prevalence of diabetes was 15·3% (95% prediction interval 2·5-36·1; I2 99·8%), varying from 0·1% in Latvia to 45·2% in Marshall Islands. Subgroup and metaregression analyses for identifying sources of heterogeneity showed that four International Diabetes Federation (IDF) regions (North America and Caribbean [19·7%], western Pacific [19·4%], southeast Asia [19·0%], Middle East and North Africa [17·5%]) had significantly higher prevalence estimates than the three others (Africa [8·0%], South and Central America [7·7%], and Europe [7·5%]; p<0·0001). Additionally, the prevalence increased with age, in men, and in countries with low tuberculosis burden. The prevalence of diabetes was decreased in countries that had low incomes and low Human Development Index scores. The form of tuberculosis infection and presence of HIV seemed not to affect the prevalence of diabetes among patients with active tuberculosis. INTERPRETATION: This study suggests a high burden of diabetes among patients with active tuberculosis, with disparities according to age, sex, regions, level of country income, and development. Cost-effective strategies to curb the burden of diabetes among patients with active tuberculosis are needed. FUNDING: None.
Authors: Clare E Warrell; Aung Pyae Phyo; Mo Mo Win; Alistair R D McLean; Wanitda Watthanaworawit; Myo Maung Maung Swe; Kyaw Soe; Htet Naing Lin; Yee Yee Aung; Chitmin Ko Ko; Cho Zin Waing; Kaung San Linn; Yadanar Phoo Wai Aung; Ne Myo Aung; Ni Ni Tun; David A B Dance; Frank M Smithuis; Elizabeth A Ashley Journal: Trans R Soc Trop Med Hyg Date: 2021-08-02 Impact factor: 2.184
Authors: Chuan De Foo; Pami Shrestha; Leiting Wang; Qianmei Du; Alberto L García-Basteiro; Abu Saleh Abdullah; Helena Legido-Quigley Journal: PLoS Med Date: 2022-01-18 Impact factor: 11.069
Authors: Anthony D Harries; Ajay M V Kumar; Srinath Satyanarayana; Pruthu Thekkur; Yan Lin; Riitta A Dlodlo; Mohammed Khogali; Rony Zachariah Journal: Trop Med Infect Dis Date: 2020-04-16